Inhibitors of tyrosine kinases and uses thereof

Details Inhibitors of tyrosine kinases and uses thereof Inhibitors of tyrosine kinases and uses thereof

2009-10-07

2011-11-29

Shiao, Rei-tsang (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C514S252130

Reexamination Certificate

active

08067395

ABSTRACT:
Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.

REFERENCES:
patent: 6326469 (2001-12-01), Ullrich et al.
patent: 6506769 (2003-01-01), Snow et al.
patent: 6660744 (2003-12-01), Hirst et al.
patent: 6753348 (2004-06-01), Uckun et al.
patent: 6770639 (2004-08-01), Snow et al.
patent: 6921763 (2005-07-01), Hirst et al.
patent: 7625880 (2009-12-01), Jankowski
patent: 2002/0016460 (2002-02-01), Snow et al.
patent: 2003/0040461 (2003-02-01), Mcatee
patent: 2003/0125235 (2003-07-01), Foxwell
patent: 2003/0166929 (2003-09-01), Snow et al.
patent: 2005/0008640 (2005-01-01), Waegell et al.
patent: 2005/0090499 (2005-04-01), Currie et al.
patent: 2005/0101604 (2005-05-01), Currie et al.
patent: 2005/0196851 (2005-09-01), Uckun
patent: 2005/0209255 (2005-09-01), Jimenez et al.
patent: 2006/0167090 (2006-07-01), Uckun et al.
patent: WO-97-28161 (1997-08-01), None
patent: WO-00-56737 (2000-09-01), None
patent: WO-01-19829 (2001-03-01), None
patent: WO-01-25238 (2001-04-01), None
patent: WO-01-19829 (2001-06-01), None
patent: WO-01-41754 (2001-06-01), None
patent: WO-01-44258 (2001-06-01), None
patent: WO-02-38797 (2002-05-01), None
patent: WO-02-080926 (2002-10-01), None
patent: WO-03-000187 (2003-01-01), None
patent: WO-2004-096253 (2004-11-01), None
patent: WO-2005-005429 (2005-01-01), None
patent: WO-2005-014599 (2005-02-01), None
Browning, J.L., “B cells move to centre stage: novel opportunities for autoimmune disease treatment”, Nature Reviews/Drug Discovery vol. 5, Jul. 2006, pp. 564-576.
Cohen, M.S. et al., “Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors,” Science, vol. 308, May 27, 2005, pp. 1318-1321.
Desiderio, S., “Role of Btk in B cell development and signaling,” Curr. Op. in Immunology 1997, 9:534-540.
Fruman, D.A., “Xid-like Phenotypes: A B Cell Signalosome Takes Shape,” Immunity 13:1-3 (Jul. 2000).
Gold, Michael R., “To make antibodies or not:signaling by the B-cell antigen receptor,” Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).
Horwood, Nicole J. et al., “Bruton's Tyrosin Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor α Production,” J. Exp. Med. 197(12):1603-1611 (Jun. 2003).
Iwaki, Shoki et al., “Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit,” J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).
Jefferies, Caroline A. et al., “Bruton's Tyrosine Kinase Is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor {acute over (κ)}B Activation by Toll-like Receptor 4,” J. Biol. Chem. 278:26258-26264 (2003).
Kawakami, Yuko et al., “Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase,” PNAS USA 96:2227-2232 (1999).
Kuppers, R., “Mechanisms of B-cell lymphoma pathogenesis,” Nature Reviews/Cancer, vol. 5, Apr. 2005, pp. 251-262.
Kurosaki, Tomohiro, “Functional dissection of BCR signaling pathways,” Curr. Op. Imm. 12:276-281 (2000).
Mahajan, S. et al., “Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Methyl-N-(2,5-Dibromophenyl)Propenamide],” J. of Biol. Chem., vol. 274, No. 14, Apr. 2, 1999, pp. 9587-9599.
Mangla, Anita et al., “Pleiotropic consequences of Bruton tyrosin kinase deficiency in myeloid lineages lead to poor inflammatory responses,” Blood 104(4):1191-1197 (2004).
Niiro, Hiroaki and Clark, Edward A., “Regulation of B-Cell Fate by Antigen-Receptor Signals,” Nature Reviews 2:945-956 (2002).
Oligino, Thomas J. and Dalrymple, Stacie A., “Targeting B cells for the treatment of rheumatoid arthritis,” Arthirits Res Ther 5(Suppl.4):S7-S11 (2002).
Pan, Z. et al., “Discovery of Selectable Irreversible Inhibitors for Bruton's Tyrosine Kinase,” ChemMedChem 2006, 1, 1-5.
Quek, L.S. et al., “A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen,” Curr. Biol. 8(20):1137-1140 (1998).
Sada, Kiyonao and Yamamura, Hirohei, “Protein-Tyrosine Kinases and Adaptor Proteins in FceRI-Mediated Signaling in Mast Cells,” Curr. Mol. Med. 3(1):85-94 (2003).
Schaeffer, Edward M. and Schwartzberg, Pamela L., “Tec family kinases in lymphocyte signaling and function,” Curr. Op. Imm. 12:282-288 (2000).
Science IP CAS Search, Sep. 5, 2006.
Science IP CAS Search, Mar. 16, 2006.
Merged Markush Service Search, Jun. 27, 2005.
Shaffer, A.L. et al., Lymphoid malignancies: the dark side of B-cell differentiation, Nature Reviews/Immunology, vol. 2, Dec. 2002, pp. 920-932.
Smith, C.I. Edvard et al., “The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species,” BioEssays 23:436-446 (2001).
Smolen, Josef S. and Steiner, Gunter, “Therapeutic Strategies for Rheumatoid Arthritis,” Nature Reviews 2:473-488 (2003).
Uckun, Fatih M. et al., “The Anti-leukemic Bruton's Tyrosin Kinase Inhibitor α-cyano-β-hydroxy-β-mehyl-N-(2,5-dibromophenyl)Propenamide (LFM-A13)Prevents Fatal Thromboembolism,” Leuk. Lymphoma 44(9):1569-1577 (2003).
Uckun, Fatih M. et al., “In Vivo Pharmacokinetic Features, Toxicity Profile, and Chemosensitizing Activity of α-Cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a Novel Antileukemic Agent Targeting Bruton's Tyrosine Kinase,” Clin. Cancer Res. 8:1224-1233 (2002).
Uckun, F.M., “Bruton's Tyrosin Kinase (BTK) as a Dual-Function Regulator of Apoptosis,” Biochem. Pharmacology, vol. 56, pp. 683-691, 1998.
Uckun, Fatih M. et al., “BTK as a Mediator of Radiation-Induced Apoptosis in DT-40 Lymphoma B Cells,”Science vol. 273 No. 5278, pp. 1096-1100 (1996).
Vassilev, A.O. and Uckun, F.M., “Therapeutic Potential of Inhibiting Bruton's Tyrosine Kinase, (BTK),” Current Pharmaceutical Design, 2004, 10, 1757-1766.
Vassilev,Alexei et al., “Bruton's Tyrosine Kinase as an Inhibitor of the Fas/CD95 Death-inducing Signaling Complex,” J. Biol. Chem. 274(3):1646-1656 (1999).
Yamamoto, Noriyuki et al., “The Orally Available Spleen Tyrosine Kinase Inhibitor 2-[7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicotinamide Dihydrochloride (BAY61-3606) Blocks Antigen-Induced Airway Inflammation in Rodents,” J. Pharma. And Exp. Therapeutics 306(3):1174-1181 (2003).
Luskova, P. and Draber, P., “Modulation of the Fce Receptor I Signaling by Tyrosin Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases,” Curr. Pharmaceutical Design 10:1727-1737 (2004).
PCT/US06/49489 Search Report dated Dec. 28, 2007.
Arnold, L.D. et al., “Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck 1,” Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).
Burchat et al., “Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight,” Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).
Nisitani, S. et al., “In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies,” PNAS USA 96:2221-2226 (1999).
Smaill, J.B. et al., “Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)prido[d]pyrimidine Acrylamides as Irresversible Inhibitors of the ATP Binding Site of the Epidermal Growth

Affiliated with

Also associated with

Rating

Inhibitors of tyrosine kinases and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of tyrosine kinases and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of tyrosine kinases and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4307866